OctoPlus is a European provider of advanced drug formulation and clinical scale manufacturing services to the pharmaceutical and biotechnology industries.
As per the agreement OctoPlus is expected to deveop a controlled release formulation of an undisclosed peptide compound.
If the evaluation is successful, the contract may progress to a full process development, manufacturing and licensing agreement.
Financial terms of the agreement are not disclosed.